Rafarma’s Global Pharmaceutical Strategy At A Glance
18 mai 2021 08h53 HE
|
RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, May 18, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is an international biotechnological and pharmaceutical company that combines research centers and modern...
Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives
28 janv. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is...
Rise in Radioligand Therapies to Drive Global Radiopharmaceuticals Market till 2023: WiseGuyReports
11 juin 2019 09h09 HE
|
WiseGuy Research Consultants Pvt. Ltd.
Pune, India, June 11, 2019 (GLOBE NEWSWIRE) -- Radiopharmaceuticals are a group of compounds used for discerning the presence of abnormalities in tissues, organs, or cells. They are a vital...
Global Radiopharmaceuticals in Nuclear Medicine Market to Surpass US$ 10.6 Billion by 2026 – Coherent Market Insights
10 mai 2019 08h30 HE
|
CMI
SEATTLE, May 10, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global radiopharmaceuticals in nuclear medicine market was valued at US$ 4,986.4 million in 2017 and is projected to...
GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments
09 oct. 2018 18h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
02 mai 2018 03h10 HE
|
Curium
Paris, May 02, 2018 (GLOBE NEWSWIRE) -- Curium has successfully completed its previously announced acquisition of the French commercial and manufacturing operations of Cyclopharma, a leading...
Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
14 janv. 2018 21h12 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO Japan, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...
Telix Pharmaceuticals and JFE Announce Japanese Radiopharmaceutical Manufacturing Partnership
12 déc. 2017 17h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and TOKYO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development...
Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange
14 nov. 2017 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of...
Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
19 sept. 2017 21h46 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company) is pleased to announce the conclusion of a collaboration and licensing...